Jovana Komazec is a molecular biologist specializing in the study of the genetic basis of rare and monogenic diseases. She graduated in Molecular Biology and Physiology from the Faculty of Biology, University of Belgrade, in 2012. She completed her PhD studies at the same institution in 2020, focusing her research on the molecular-genetic mechanisms of a specific form of diabetes known as Maturity-Onset Diabetes of the Young (MODY). During her doctoral research, she identified known pathogenic variants in relevant genes, discovered and functionally characterized novel variants, and investigated genotype–phenotype correlations.

Through continuous laboratory work and professional development, she has acquired strong skills in the application of molecular biology techniques, with particular expertise in next-generation sequencing on the Illumina platform. She applies these methods in both research and diagnostic settings, especially in the field of rare diseases.

She is currently involved in several projects: the national project GlucoAdjust, aimed at developing small-molecule drugs for the treatment of GSD Ib and type 2 diabetes by targeting the G6PT protein; the international project BETTER, which enables secure, GDPR-compliant, AI-driven analysis of healthcare data from multiple countries to advance personalized medicine; and the BRIDGING-RD project, focused on strengthening rare disease research through improved biobank interoperability, development of bioinformatics tools, and promotion of translational research for new therapies. As a member of multidisciplinary teams, she actively participates in experimental research and the development of biomedical research infrastructure. Her interests also include biobanking, with a focus on standardizing sample collection, improving data management, and increasing the interoperability of research resources.